Navigation Links
Sinovac to Present at 23rd Annual Piper Jaffray Health Care Conference and HK/China Mini Conference 2011 (Healthcare)
Date:11/23/2011

BEIJING, Nov. 23, 2011 /PRNewswire-Asia/ -- Sinovac Biotech Ltd. (Nasdaq: SVA), a leading provider of vaccines in China, today announced that management is scheduled to present at the 23rd Annual Piper Jaffray Health Care Conference that will be held on November 29th and 30th at The New York Palace in New York City, and to participate in HK/China Mini Conference 2011 (Healthcare) on December 1, 2011 at Island Shangri-La Hotel, Hong Kong.  

Ms. Helen Yang, Sinovac's Investor Relations Director, will present on November 30th at 10:30 am ET at the 23rd Annual Piper Jaffray Health Care Conference and will be participating in one-on-one meetings.

Ms. Nan Wang, Sinovac's Interim CFO and Chris Lee, Investor Relations, will be participating in one-on-one meetings at HK/China Mini Conference 2011 (Healthcare) on December 1, 2011.

About Sinovac

Sinovac Biotech Ltd. is a China-based biopharmaceutical company that focuses on the research, development, manufacture and commercialization of vaccines that protect against human infectious diseases including hepatitis A, seasonal influenza, H5N1 (bird flu) pandemic influenza and H1N1 influenza. In 2009, Sinovac was the first company worldwide to receive approval for its H1N1 influenza vaccine, PANFLU.1, and has received orders from the Chinese Central Government pursuit to the government stockpiling program. The Company is developing a number of new vaccine products, including vaccines for pneumococcal conjugate, enterovirus 71 (EV71) (against Hand, Foot & Mouth Disease), pneumococcal polysaccharides, human rabies, HIB, rotavirus and epidemic meningitis, chickenpox and mumps & rubella. Its wholly owned subsidiary, Tangshan Yian, is focusing on the research, development, manufacturing and commercialization of animal vaccines, and has launched its internally developed inactivated rabies vaccine in China.

Safe Harbor Statement

This announcement contains forward-looking statements. These statements are made under the "safe harbor" provisions of the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by words or phrases such as "will," "expects," "anticipates," "future," "intends," "plans," "believes," "estimates" and similar statements. Among other things, the business outlook and quotations from management in this press release contain forward-looking statements. Statements that are not historical facts, including statements about Sinovac's beliefs and expectations, are forward-looking statements. Forward-looking statements involve inherent risks and uncertainties. A number of important factors could cause actual results to differ materially from those contained in any forward-looking statement. Sinovac does not undertake any obligation to update any forward-looking statement, except as required under applicable law.

Helen Yang/Chris Lee
Sinovac Biotech Ltd.
Tel:  +86-10-8279-9871/9659
Fax:  +86-10-6296-6910
Email: ir@sinovac.com

Investors:
Stephanie Carrington
The Ruth Group
Tel:  +1-646-536-7017
Email: scarrington@theruthgroup.com

Media
Victoria Aguiar
The Ruth Group
Tel:  +1-646-536-7013
Email:  vaguiar@theruthgroup.com


'/>"/>
SOURCE Sinovac Biotech Ltd.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. /C O R R E C T I O N -- Sinovac Biotech Ltd./
2. Sinovac Reports Unaudited Third Quarter 2011 Financial Results
3. Sinovac Reports Positive Preliminary Phase II Clinical Trial Results for EV71 Vaccine Against Hand, Foot and Mouth Disease
4. Sinovac to Host Conference Call to Report Third Quarter 2011 Unaudited Financial Results
5. Sinovac Reports Unaudited Second Quarter 2011 Financial Results
6. Sinovac Announces Management Changes
7. Sinovac Holds 2011 Annual Shareholders Meeting
8. Sinovac Appoints Kenneth Lee to Board of Directors
9. Sinovac Reports Positive Phase I Clinical Trial Results for EV71 Vaccine Candidate Against Hand, Foot & Mouth Disease(HFMD)
10. Sinovac Reports Unaudited First Quarter 2011 Financial Results
11. Sinovac Presents at Two Investor Conferences in May 2011
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/8/2017)... 8, 2017 MACRA replaces the outdated ... for service reimbursement. Black Book Research crowdsource-surveyed 8,845 physician ... 1.       The Market for MIPS Compliance Technology is Booming ... practices with 3 or more clinicians seek to buy ... "Given the magnitude of the changes, the hunt is ...
(Date:5/6/2017)... is Stroke Awareness Month and Omron Healthcare is reminding ... prevent a stroke: monitor and manage your blood pressure. ... undetected and uncontrolled hypertension is a leading risk factor ... personal heart health technology, recently evolved its mission to ... and is advancing a national public education effort to ...
(Date:5/4/2017)...  A recent study published in the American ... as a means of disinfection anesthesia workstations ... on anesthesia workstations. In the study, UVC disinfection ... equipment surfaces contaminated with three (3) organisms commonly ... further validates the body of literature supporting Tru-D," ...
Breaking Medicine Technology:
(Date:5/24/2017)... Massapequa Park, NY (PRWEB) , ... May 24, ... ... today announced the practice is offering holistic pediatric dentistry options for its patients ... the context of the patient’s entire physical well being, and is one of ...
(Date:5/24/2017)... ... 2017 , ... Dymedix® Diagnostics, Inc., the leading ... had completed the first phase of building a global distribution network. To date, ... (ROW) authorized dealers specializing in polysomnography accessories. The company plans to expand ...
(Date:5/23/2017)... ... May 23, 2017 , ... Cambridge, MA, May ... since 2009, according to a Workers Compensation Research Institute (WCRI) study, a contrast ... North Carolina System: CompScope™ Benchmarks, 17th Edition looks at indemnity and medical ...
(Date:5/23/2017)... ... May 23, 2017 , ... The Gallery of Cosmetic Surgery, ... pleased to announce a new treatment option called Vivace Microneedling. This treatment option ... and body through a virtually pain-free, non-surgical treatment. Vivace Microneedling combines a state-of-the-art, ...
(Date:5/23/2017)... ... May 23, 2017 , ... New patients from Charleston, SC, are now welcome ... in Mt. Pleasant, SC, with or without a referral. A full mouth reconstruction can ... missing teeth in Charleston, SC. Those who suffer from gum disease, misaligned teeth ...
Breaking Medicine News(10 mins):